Table 2.
Clinical parameters associated with response and survival post inotuzumab ozogamicin therapy.*
| Clinical features | n | Marrow CR, n (%) | UVA |
MVA |
Median survival, months | UVA |
MVA |
||
|---|---|---|---|---|---|---|---|---|---|
| p | OR | p | p | HR | p | ||||
| Platelets, × 109/l | |||||||||
| <100 | 71 | 35 (49) | <0.001 | 11.5 | 0.03 | 5.0 | <0.001 | NA | NS |
| ⩾100 | 18 | 17 (94) | NR | ||||||
| ABC, × 109/l | |||||||||
| <1.0 | 58 | 43 (74) | <0.001 | 6.8 | <0.001 | 7.8 | <0.001 | 1.7 | 0.02 |
| ⩾1.0 | 31 | 9 (29) | 4.3 | ||||||
| Dose schedule | |||||||||
| Weekly | 40 | 24 (60) | 0.79 | NA | NA | 9.5 | 0.03 | NA | NS |
| Single dose | 49 | 28 (57) | 5.0 | ||||||
| Treatment status | |||||||||
| Salvage 1 | 29 | 22 (76) | 0.02 | NA | NS | 10.2 | <0.001 | 2.3 | 0.007 |
| >Salvage 1 | 60 | 30 (50) | 4.8 | ||||||
| Karyotype | |||||||||
| Diploid | 17 | NS | 0.05 | NA | NS | 44.0 | <0.001 | 2.9 | 0.01 |
| Other | 10 | ||||||||
| Complex | 24 | 5.0 | |||||||
| Abnormal Ch 17 | 11 | ||||||||
| Ph-positive | 17 | ||||||||
| Translocation (4;11) | 9 | ||||||||
ABC, peripheral blood absolute blast count; Ch: chromosome; CR, complete response; HR, hazard ratio; MVA, multivariate analysis; Ph: Philadelphia chromosome; NA, not applicable; NR, not reported; NS, not significant; OR, odds ratio; UVA, univariate analysis.